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INTRODUCTION 
 
In the United States, acute liver failure (ALF) affects an estimated 2,000 
people per year and accounts for 6% of all liver transplants. Without 
transplantation, however, less than 50% of patients survive with medical 
management alone. Early identification of patients with survivable AFL is 
important to guiding their management and early referral to 
transplantation. 
 
Studies have shown that the current prognostic scoring systems used for 
FHF, including the King’s College Criteria (KCC) and the Model for End-
Stage Liver Disease (MELD), have poor sensitivity and negative predictive 
value for predicting outcome, highlighting a need for more accurate 
predictive models. 
 
Ki-67 is a well-established marker of cellular proliferation but its 
expression in FHF as a surrogate marker of liver regeneration has not 
been studied as a tool to predict outcome in these patients. 
 
In this pilot study, we sought to determine the predictive value of Ki-67 
expression in patients with FHF and its potential for improving the 
accuracy of current predictive models. 
METHODS 
 
A retrospective analysis was performed on patients admitted to Thomas 
Jefferson University Hospital (Philadelphia, PA) with ALF between 2000 
and 2014 who underwent liver biopsies as part of their management. 
Under IRB approval, the surgical pathology database at TJUH was 
searched for biopsies with the keywords “confluent”, “submassive”, or 
“massive hepatic necrosis”. The identified liver biopsies and medical 
records were reviewed, and all patients with confirmed confluent hepatic 
necrosis and acute liver failure were selected. Thirty patients were 
identified as meeting inclusion criteria and constituted the study. 
The medical records of all 30 patients were reviewed and the 
demographic, laboratory, and clinical outcome data (survival with or 
without liver transplantation) were obtained. 
 
The liver biopsies were sectioned and immunohistochemical staining for 
Ki-67 was performed. Ki-67 expression was assessed by an independent 
pathologist and categorized as either proliferative (numerous Ki-67 
positive hepatocytes) or non-proliferative (few if any positive cells).  
The clinical information obtained was used to calculate MELD scores and 
determine if KCC were met. Ki-67 expression, MELD score and KCC were 
correlated with the patient outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Proliferative liver biopsy by Ki-67 stain in patients with ALF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Non-proliferative liver biopsy by Ki-67 stain in patients with 
ALF 
 
RESULTS 
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Predictive Accuracy of Ki-67 for Outcome in Patients with FHF 
§  Among non-transplanted patients, Ki-67 had a sensitivity  of 100% and a 
specificity of 69%. A proliferative biopsy had a 100% predictive value for 
survival. 
§  For all patients, Ki-67 had a sensitivity and specificity of 65% and 69% 
respectively. A non-proliferative biopsy had a predictive value for death or 
transplant of 73%. 
 
 
 
 
 
 
 
 
 
Table 3. Predictive Accuracy of Various Prognostic Models for FHF 
§  A composite score requiring at least 2 of the 3 prognostic criteria resulted in 
a predictive value of 94% for death or transplantation and an overall 
diagnostic accuracy of 90%, both greater than any  one of the criteria alone. 
CONCLUSION 
The results of this study show that the evaluation of liver biopsies for Ki-67 
expression provides a useful adjunct to established criteria in determining the 
prognosis of patients with fulminant liver failure.  
 
Larger studies should be performed to determine the true import of Ki-67 
activity in such patients. 
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Figure 3. Overall Diagnostic Accuracy of Ki-67 for Outcome in FHF 
Table 1. Demographic Profile of the Study Population 
Demographic n (%) 
Mean Age 46.7 ± 16 
Male/Female 12 (40%)/18 (60%) 
Etiology of FHF:   
     Acetaminophen 3 (10%) 
     Viral Hepatitis 7 (23%) 
     Drug-Induced 5 (17%) 
     Autoimmune 10 (33%) 
     Unknown 5 (17%) 
Outcome:   
     Spontaneous Survival 13 (43%) 
     Transplant 13 (43%) 
     Death 4 (13%) 
Group 
Proliferativ
e Biopsy 
Non-
Proliferative 
Biopsy 
Tota
l 
Sensitivit
y 
Specificit
y PPV NPV 
Non-Transplanted 
Patients 100% 69% 50% 100% 
     Survival 9 4 13 
     Death 0 4 4 
     Total 9 8 17 
All Patients 65% 69% 73% 60% 
     Survival 9 4 13 
     Death/
Transplant 
6 (0/6) 11 (4/7) 17 
     Total 15 15 30 
Model Sensitivity 
Specificit
y PPV NPV 
Overall 
Diagnostic 
Accuracy 
King’s College Criteria 53% 92% 90% 60% 70% 
MELD > 32 88% 69% 79% 82% 80% 
Non-Proliferative Biopsy by 
Ki-67 
65% 69% 73% 60% 67% 
2 or 3 Criteria (KCC, MELD > 
32, Non-Proliferative Biopsy 
by Ki-67) 
88% 92% 94% 86% 90% 
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